Omnicell (OMCL) AI Stock Analysis

Compare

334 Followers

Top Page

Omnicell

(NASDAQ:OMCL)

Select Model

Neutral 69 (OpenAI - 4o)

Rating:69Neutral

Price Target:

$37.00

▼(-8.64% Downside)

Omnicell's overall stock score reflects a stable financial position and strong technical momentum. The company's strategic initiatives and product adoption indicate positive momentum, but high valuation and profitability challenges weigh on the score. The earnings call provided a positive outlook, though tariff impacts and slower growth in certain areas present risks.

Positive Factors

Recurring Revenue Growth

The focus on recurring revenue through subscription models and platform expansion ensures stable, predictable income, enhancing long-term financial stability.

Product Innovation

Continuous product innovation strengthens competitive positioning and meets evolving customer needs, driving future revenue growth and market share.

Cybersecurity Certification

Achieving cybersecurity certification enhances trust and operational excellence, crucial for sustaining partnerships with healthcare providers concerned about data security.

Negative Factors

Revenue Decline

A decline in revenue indicates potential challenges in market demand or competitive pressures, which could impact long-term growth if not addressed.

Operational Efficiency

Low operational efficiency, as indicated by weak margins, suggests difficulties in cost management, which could hinder profitability and cash flow generation.

Tariff Impacts

Tariff impacts on profitability highlight external risks that could affect margins and financial performance if mitigation strategies are insufficient.

Omnicell (OMCL) vs. SPDR S&P 500 ETF (SPY)

Market Cap

$1.82B

Dividend YieldN/A

Average Volume (3M)450.30K

Price to Earnings (P/E)95.0

Beta (1Y)0.22

Revenue Growth10.67%

EPS GrowthN/A

CountryUS

Employees3,620

SectorHealthcare

Sector Strength45

IndustryMedical - Healthcare Information Services

Share Statistics

EPS (TTM)0.51

Shares Outstanding44,876,522

10 Day Avg. Volume405,702

30 Day Avg. Volume450,304

Financial Highlights & Ratios

PEG Ratio-1.02

Price to Book (P/B)1.65

Price to Sales (P/S)1.84

P/FCF Ratio13.55

Enterprise Value/Market Cap0.76

Enterprise Value/Revenue1.17

Enterprise Value/Gross Profit2.67

Enterprise Value/Ebitda11.71

Forecast

1Y Price Target

$40.67

Price Target Upside0.42% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)1.69

Revenue Forecast (FY)$1.18B

Omnicell Business Overview & Revenue Model

Company DescriptionOmnicell, Inc. is a healthcare technology company that specializes in medication management solutions and supply chain automation. Founded in 1992 and headquartered in Mountain View, California, Omnicell operates primarily in the healthcare sector, providing innovative products and services designed to improve patient safety, enhance operational efficiency, and streamline pharmacy and medication management processes. Its core offerings include automated medication dispensing systems, pharmacy management software, and inventory management solutions, which are utilized by hospitals, long-term care facilities, and outpatient pharmacies.

How the Company Makes MoneyOmnicell generates revenue through multiple streams, primarily by selling its automated dispensing systems and software solutions to healthcare providers. The company earns a significant portion of its revenue from the sale of hardware, including automated medication dispensing units and robotic systems. In addition to hardware sales, Omnicell also offers software solutions, maintenance contracts, and services that enhance the operational capabilities of its clients, creating recurring revenue through subscription and service contracts. Furthermore, strategic partnerships with healthcare organizations and technology providers contribute to its earnings by expanding market reach and integrating its solutions into existing healthcare infrastructures. The combination of these revenue streams allows Omnicell to maintain a robust financial model, driven by ongoing demand for healthcare efficiency and safety improvements.

Omnicell Key Performance Indicators (KPIs)

Any

Gross Profit by Segment

Gross Profit by Segment
Analyzes profitability across different business segments, highlighting which areas contribute most to the bottom line and where there might be opportunities or challenges.

Chart InsightsOmnicell's Product segment gross profit has been volatile, with a notable decline in early 2024, but recent quarters show recovery. The Service segment displays steady growth, underscoring a strategic shift towards recurring revenue. The latest earnings call highlights strong revenue growth and successful product launches, which could bolster future profitability. However, tariff impacts and rising inventory levels pose challenges. The company's focus on technology platform expansion, particularly the certified OmniSphere platform, suggests a commitment to long-term growth and operational excellence.

Data provided by:

The Fly

Omnicell Earnings Call Summary

Earnings Call Date:Oct 30, 2025

(Q3-2025)

% Change Since: |

Next Earnings Date:Feb 05, 2026

Earnings Call Sentiment Neutral

The earnings call highlighted strong revenue growth and successful execution against guidance, particularly in point-of-care solutions and the OmniSphere platform. However, there were notable challenges including a decrease in both GAAP and Non-GAAP EPS, tariff impacts on profitability, and slower growth in certain service revenues. Despite these challenges, the company's strategic initiatives and product adoption indicate positive momentum.

Q3-2025 Updates

Positive Updates

Strong Revenue Growth

Total revenue for Q3 2025 was $311 million, representing a 10% increase compared to Q3 2024 and a 7% increase compared to the previous quarter.

Exceeding Guidance

The company exceeded the upper end of its previously issued guidance for total revenues, non-GAAP EBITDA, and non-GAAP EPS.

OmniSphere Platform Success

Positive customer feedback on the OmniSphere cloud-based platform, which achieved HITRUST CSF i1 certification, highlighting cybersecurity and data protection.

Strong Point-of-Care Solutions Adoption

Continued demand for point-of-care connected devices, including XTExtend, drove robust top-line performance.

Stock Repurchase Program

Substantially completed the $75 million stock repurchase program, reducing outstanding share count by 5%.

Negative Updates

GAAP Earnings Per Share Decline

Q3 2025 GAAP EPS was $0.12, down from $0.19 in Q3 2024, indicating a decline in GAAP profitability.

Non-GAAP EPS Decrease

Non-GAAP EPS for Q3 2025 was $0.51, down from $0.56 in the same period last year.

Tariff Impact on Profitability

Tariffs impacted profitability by approximately $6 million net of mitigation efforts in Q3 2025, anticipated to continue in Q4 2025.

Decreased Cash and Cash Equivalents

Cash and cash equivalents totaled $180 million as of September 30, 2025, down from $399 million as of June 30, 2025, due to debt repayment and stock repurchase.

SaaS and Expert Services Revenue Growth Slower

Slower than expected growth in SaaS and Expert Services revenue, particularly within the EnlivenHealth business facing headwinds in the retail pharmacy space.

Company Guidance

During Omnicell's Third Quarter 2025 Financial Results Call, the company exceeded the upper end of its previously issued guidance for total revenues, non-GAAP EBITDA, and non-GAAP EPS. The company reported total revenue of $311 million, marking a 10% increase over the same period in 2024 and a 7% increase from the previous quarter. Non-GAAP earnings per share were $0.51, compared to $0.56 in the third quarter of 2024 and $0.45 in the prior quarter. Non-GAAP EBITDA was $41 million, up from $39 million in the previous year. Omnicell completed a $75 million stock repurchase program, which reduced its outstanding share count by 5%. The company highlighted ongoing demand for its point-of-care solutions and the strong adoption of its OmniSphere cloud-based platform. Guidance for the fourth quarter of 2025 anticipates total revenues between $306 million and $316 million, with non-GAAP EPS expected to be between $0.40 and $0.50. For the full year 2025, Omnicell raised its revenue guidance to between $1.177 billion and $1.187 billion and increased its non-GAAP EPS guidance to between $1.63 and $1.73.

Omnicell Financial Statement Overview

Summary

Omnicell demonstrates a stable financial position with a strong balance sheet and positive cash flow trends. Revenue and profit margins are improving, but operational efficiency remains a challenge. The company is well-positioned with low leverage, but enhancing profitability and cash flow coverage could further strengthen its financial health.

Income Statement

Positive

Omnicell's income statement shows moderate performance with a gross profit margin of 43.7% and a net profit margin of 1.7% for TTM. The company has demonstrated revenue growth of 2.5% in the TTM period, recovering from a previous decline. However, the EBIT and EBITDA margins are relatively low, indicating potential challenges in operational efficiency.

Balance Sheet

Positive

The balance sheet reflects a strong equity position with a debt-to-equity ratio of 0.16, indicating low leverage and financial stability. The return on equity is modest at 1.6%, suggesting limited profitability from shareholders' equity. The equity ratio is healthy, supporting the company's financial resilience.

Cash Flow

Positive

Omnicell's cash flow statement shows positive trends with an 8.9% growth in free cash flow. The operating cash flow to net income ratio is 0.34, and the free cash flow to net income ratio is 0.73, indicating efficient cash generation relative to net income. However, there is room for improvement in cash flow coverage.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.18B	1.11B	1.15B	1.30B	1.13B	892.21M
Gross Profit	516.04M	471.00M	499.93M	588.99M	554.65M	413.29M
EBITDA	117.75M	90.09M	79.98M	96.85M	174.44M	107.12M
Net Income	19.92M	12.53M	-20.37M	5.65M	77.85M	32.19M
Balance Sheet
Total Assets	1.95B	2.12B	2.23B	2.21B	2.14B	1.82B
Cash, Cash Equivalents and Short-Term Investments	193.45M	381.68M	467.97M	341.85M	359.72M	496.17M
Total Debt	206.78M	382.55M	614.09M	616.74M	541.01M	528.29M
Total Liabilities	727.70M	877.65M	1.04B	1.08B	995.81M	857.00M
Stockholders Equity	1.22B	1.24B	1.19B	1.13B	1.15B	967.50M
Cash Flow
Free Cash Flow	111.47M	151.26M	139.62M	17.04M	202.84M	131.00M
Operating Cash Flow	153.26M	187.72M	181.09M	77.78M	231.81M	185.87M
Investing Cash Flow	-59.51M	-52.79M	-55.02M	-58.67M	-412.50M	-279.87M
Financing Cash Flow	-461.84M	-235.58M	23.42M	-20.95M	47.36M	456.27M

Omnicell Technical Analysis

Technical Analysis Sentiment

Positive

Last Price40.50

Price Trends

50DMA

33.34

Positive

100DMA

32.23

Positive

200DMA

31.84

Positive

Market Momentum

MACD

1.69

Negative

RSI

71.71

Negative

STOCH

91.59

Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OMCL, the sentiment is Positive. The current price of 40.5 is above the 20-day moving average (MA) of 36.61, above the 50-day MA of 33.34, and above the 200-day MA of 31.84, indicating a bullish trend. The MACD of 1.69 indicates Negative momentum. The RSI at 71.71 is Negative, neither overbought nor oversold. The STOCH value of 91.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OMCL.

Omnicell Risk Analysis

Omnicell disclosed 33 risk factors in its most recent earnings report. Omnicell reported the most risks in the "Production" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added 0 New Risks

Omnicell Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
OMCL	69 Neutral	$1.82B	94.97	1.62%	―	10.67%	―
GDRX	65 Neutral	$919.86M	31.55	4.90%	―	1.30%	―
CERT	63 Neutral	$1.47B	136.80	1.03%	―	11.47%	―
TXG	60 Neutral	$2.25B	―	-10.12%	―	1.92%	59.18%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
EVH	47 Neutral	$439.71M	―	-13.63%	―	-16.65%	-71.92%
TDOC	47 Neutral	$1.35B	―	-15.42%	―	-2.37%	77.85%

* Healthcare Sector Average

Performance Comparison

OMCL

Omnicell

40.50

-6.60

-14.01%

EVH

Evolent Health

3.94

-7.13

-64.41%

TDOC

Teladoc

7.59

-3.10

-29.00%

TXG

10x Genomics

17.77

1.62

10.03%

GDRX

GoodRx Holdings

2.71

-2.25

-45.36%

CERT

Certara

9.22

-2.29

-19.90%

Omnicell Corporate Events

Business Operations and StrategyRegulatory Filings and Compliance

Omnicell Updates Bylaws for Enhanced Governance

Neutral

Oct 6, 2025

On September 30, 2025, Omnicell, Inc.’s board of directors adopted the fourth amended and restated bylaws, effective immediately. These amendments enhance procedural mechanics and disclosure requirements for stockholder nominations and proposals, address matters related to Rule 14a-19 under the Exchange Act, clarify personal jurisdiction provisions, and make various updates, impacting the company’s governance and stakeholder engagement.

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Nov 12, 2025